Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Spondylitis, Ankylosing 1Psoriasis 1Lymphoma, Follicular 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × secukinumab × Clear all
NCT06833112 2025-02-18

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

The Affiliated Hospital Of Guizhou Medical University

Phase 4 Not yet recruiting
10 enrolled

Spondylitis, Ankylosing

NCT04571567 2022-04-11

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Icahn School of Medicine at Mount Sinai

Phase 4 Completed
20 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡